Clinical Trial Update: Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma (Cancer) of the Prostate [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating docetaxel with or without oblimersen for hormone-refractory prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Genasense (oblimersen)
• Taxotere (docetaxel)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED